Financial reports
10-Q
2023 Q2
Quarterly report
12 Feb 24
10-Q
2023 Q1
Quarterly report
8 Nov 23
10-K
2023 FY
Annual report
16 Aug 23
10-Q
2023 Q3
Quarterly report
12 May 23
10-Q
2022 Q2
Quarterly report
10 Feb 23
10-Q
2022 Q1
Quarterly report
4 Nov 22
10-K
2022 FY
Annual report
27 Sep 22
10-Q
2022 Q3
Quarterly report
11 May 22
10-Q
2022 Q2
Quarterly report
8 Feb 22
10-Q
2022 Q1
Quarterly report
10 Nov 21
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Apr 24
8-K
BioVie Announces Pipeline Update and Near-Term Clinical Priorities
11 Mar 24
8-K
BioVie Inc. Announces Closing of Public Offering
6 Mar 24
8-K/A
Financial Statements and Exhibits
4 Mar 24
8-K
BioVie Inc. Announces Proposed Public Offering of Common Stock
4 Mar 24
8-K
Other Events
1 Mar 24
8-K
Other Events
25 Jan 24
8-K
Other Events
19 Jan 24
8-K
BioVie Announces EfficacyData from Phase 3 Trial of NE3107 in Patientswith Mild to Moderate Alzheimer’s Disease
29 Nov 23
8-K
Submission of Matters to a Vote of Security Holders
13 Nov 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
4 Mar 24
424B5
Prospectus supplement for primary offering
1 Mar 24
424B3
Prospectus supplement
19 Jan 24
424B3
Prospectus supplement
28 Aug 23
S-3
Shelf registration
18 Aug 23
424B3
Prospectus supplement
14 Apr 23
424B5
Prospectus supplement for primary offering
6 Apr 23
S-3
Shelf registration
31 Mar 23
424B5
Prospectus supplement for primary offering
23 Dec 22
424B5
Prospectus supplement for primary offering
14 Dec 22
Proxies
DEF 14A
Definitive proxy
29 Sep 23
DEF 14A
Definitive proxy
30 Sep 22
DEF 14C
Information statement
25 Jul 22
PRE 14C
Preliminary information
15 Jul 22
DEF 14A
Definitive proxy
13 Sep 21
DEFM14C
Information related to merger
20 May 21
PRER14C
Preliminary revised information
10 May 21
PREM14C
Preliminary information related to merger
4 May 21
DEF 14C
Information statement
8 May 19
PRE 14C
Preliminary information
29 Apr 19
Other
EFFECT
Notice of effectiveness
29 Aug 23
UPLOAD
Letter from SEC
25 Aug 23
CORRESP
Correspondence with SEC
24 Aug 23
EFFECT
Notice of effectiveness
11 Apr 23
CORRESP
Correspondence with SEC
7 Apr 23
UPLOAD
Letter from SEC
6 Apr 23
CORRESP
Correspondence with SEC
6 Apr 23
EFFECT
Notice of effectiveness
3 Feb 21
CORRESP
Correspondence with SEC
1 Feb 21
UPLOAD
Letter from SEC
29 Jan 21